XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. cells, receptors) to treat disease.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

OCTOBER 12, 2022

When the microvasculature within the tumor is destroyed, the tumor is deprived of oxygen and nutrients, and this leads to cell death in the tumor tissue from ischemia and hemorrhagic necrosis. It is also easy to apply for the kidneys because only the renal arteries feed the kidneys,” explained Ashton. Figure from Liu et al.,

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

The Pharma Data

MAY 4, 2021

and developed Europe following the approvals in 2019 for combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced renal cell carcinoma; as well as. Inlyta globally, up 34% operationally, primarily reflecting increased demand in the U.S. Amy Rose 212.733.7410.

Vaccination 40

Vaccination Vaccine Production Sales 40